2,6-dichloro-7-(ethoxycarbonylmethyl)-7H-purine | 1585965-77-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,6-dichloro-7-(ethoxycarbonylmethyl)-7H-purine
• 英文别名: Ethyl 2-(2,6-dichloropurin-7-yl)acetate；ethyl 2-(2,6-dichloropurin-7-yl)acetate
• CAS: 1585965-77-0
• 化学式: C₉H₈Cl₂N₄O₂
• 分子量: 275.094
• InChiKey: NRQZARNLPNOAKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.9
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-7-(ethoxycarbonylmethyl)-7H-purine 在 bis[1,2-bis(diphenylphosphino)ferrocene]-palladium(0) 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 144.0h， 生成
  参考文献：
  名称：

  [EN] COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
  [FR] COMPOSÉS INTERAGISSANT AVEC LA SUPERFAMILLE RAS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS, DE MALADIES INFLAMMATOIRES, DE RASOPATHIES ET DE MALADIES FIBROTIQUES

  摘要：

  本发明提供了治疗癌症、炎症性疾病、rasopathy症和涉及异常Ras超家族信号传导的纤维化疾病的方法和组合物，这些方法和组合物通过化合物与Ras超家族蛋白（包括在某些情况下K-Ras及其突变体）的GTP结合域的结合来实现。此外，还提供了一种用于检测这些组合物的新方法。

  公开号：

  WO2018237084A1
• 作为产物：
  描述：

  溴乙酸乙酯 、 2,6-二氯嘌呤 在 甲基氯化镁 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 以25%的产率得到2,6-dichloro-7-(ethoxycarbonylmethyl)-7H-purine
  参考文献：
  名称：

  [EN] COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
  [FR] COMPOSÉS INTERAGISSANT AVEC LA SUPERFAMILLE RAS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS, DE MALADIES INFLAMMATOIRES, DE RASOPATHIES ET DE MALADIES FIBROTIQUES

  摘要：

  本发明提供了治疗癌症、炎症性疾病、rasopathy症和涉及异常Ras超家族信号传导的纤维化疾病的方法和组合物，这些方法和组合物通过化合物与Ras超家族蛋白（包括在某些情况下K-Ras及其突变体）的GTP结合域的结合来实现。此外，还提供了一种用于检测这些组合物的新方法。

  公开号：

  WO2018237084A1

文献信息

• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：Shy Therapeutics LLC

  公开号：US10940139B2

  公开（公告）日：2021-03-09

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• Anti-proliferative activity of 2,6-dichloro-9- or 7-(ethoxycarbonylmethyl)-9H- or 7H-purines against several human solid tumour cell lines
  作者：Fátima Morales、Alberto Ramírez、Ana Conejo-García、Cynthia Morata、Juan A. Marchal、Joaquín M. Campos

  DOI：10.1016/j.ejmech.2014.02.012

  日期：2014.4

  As leads we took several benzo-fused seven- and six-membered scaffolds linked to the pyrimidine or purine moieties with notable anti-proliferative activity against human breast, colon and melanoma cancerous cell lines. We then decided to maintain the double-ringed nitrogenous bases and change the other components to the ethyl acetate moiety. This way six purine and two 5-fluorouracil derivatives were obtained and evaluated against the MCF-7, HCT-116, A-375 and G-361 cancer cell lines. Two QSARs are obtained between the anti-proliferative IC50 values for compounds 26-33 and the clog P against the melanoma cell lines A-375 and G-361. Our results show that two of the analogues [ethyl 2-(2,6-dichloro-9H- or 7H-purine-9- or 7-yl)acetates (30 and 33, respectively)] are potent cytotoxic agents against all the tumour cell lines assayed, showing single-digit micromolar IC50 values. This exemplifies the potential of our previously reported purine compounds to qualify as lead structures for medicinal chemistry campaigns, affording simplified analogues easy to synthesize and with a noteworthy bioactivity. The selective activity of 30 and 33 against the melanoma cell line A-375, via apoptosis, supposes a great advantage for a future therapeutic use. (C) 2014 Elsevier Masson SAS. All rights reserved.
• COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
  申请人：Shy Therapeutics LLC

  公开号：US20200054614A1

  公开（公告）日：2020-02-20

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
  申请人：F-STAR THERAPEUTICS, INC.

  公开号：US20220168309A1

  公开（公告）日：2022-06-02

  Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.
• [EN] COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE<br/>[FR] COMPOSÉS INTERAGISSANT AVEC LA SUPERFAMILLE RAS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS, DE MALADIES INFLAMMATOIRES, DE RASOPATHIES ET DE MALADIES FIBROTIQUES
  申请人：SHY THERAPEUTICS LLC

  公开号：WO2018237084A1

  公开（公告）日：2018-12-27

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本发明提供了治疗癌症、炎症性疾病、rasopathy症和涉及异常Ras超家族信号传导的纤维化疾病的方法和组合物，这些方法和组合物通过化合物与Ras超家族蛋白（包括在某些情况下K-Ras及其突变体）的GTP结合域的结合来实现。此外，还提供了一种用于检测这些组合物的新方法。